Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Sotorasib · Lumakras, AMG-510

Small molecule · Inhibitor of KRAS G12C (KRAS) · developed by Amgen

Approved FDA, May 2021
AMGN Developer
1 Registered trials

What is Sotorasib?

Sotorasib is a small-molecule inhibitor that forms an irreversible covalent bond with KRAS G12C, locking the protein in an inactive state and preventing downstream signaling. It blocks KRAS signaling, inhibits cell growth, and promotes apoptosis in KRAS G12C tumor cells without affecting wild-type KRAS.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Lumakras, AMG-510, LUMYKRAS, LUMAKRAS
Drug type
Small molecule
Targets
KRAS G12C (KRAS)
Mechanism
Inhibitor of KRAS G12C (KRAS)
Pathways
MAPK/ERK, PI3K/Akt
Therapy area
Oncology
Developer
Amgen Inc (AMGN)
FDA status
Approved as Lumakras (May 28, 2021), NDA214665 · FDA label
UNII
2B2VM6UC8G

✅ FDA-approved uses

From the indications section of the FDA label (version of Jan 22, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05920356 Phase 3 Non-Small Cell Lung Cancer (NSCLC) Recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-Small Cell Lung Cancer (NSCLC)

Other drugs acting on KRAS

AN9025 Phase 1 ARV-806 Phase 1/2 Calderasib Phase 3 Elironrasib Phase 1/2 ERAS-0015 Phase 1 Olomorasib Phase 3 Zoldonrasib Phase 1/2

More from Amgen

Apremilast FDA approved Blinatumomab FDA approved Carfilzomib FDA approved Denosumab FDA approved Erenumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romiplostim FDA approved Romosozumab FDA approved Tarlatamab FDA approved ABP 692 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Sotorasib

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.